Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China COVID 19 Diagnostics Market

ID: MRFR/MED/51443-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026

China COVID-19 Diagnostics Market Research Report By Test Type (PCR Tests, Antigen Tests, Antibody Tests, CRISPR Tests), By End User (Hospitals, Clinics, Laboratories, Home Care), By Sample Type (Nasopharyngeal Swabs, Oropharyngeal Swabs, Saliva, Serum) and By Distribution Channel (Direct Sales, Retail Pharmacies, Online Sales) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China COVID 19 Diagnostics Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Test Type (USD Million)
  49.     4.1.1 PCR Tests
  50.     4.1.2 Antigen Tests
  51.     4.1.3 Antibody Tests
  52.     4.1.4 CRISPR Tests
  53.   4.2 Construction, BY End User (USD Million)
  54.     4.2.1 Hospitals
  55.     4.2.2 Clinics
  56.     4.2.3 Laboratories
  57.     4.2.4 Home Care
  58.   4.3 Construction, BY Sample Type (USD Million)
  59.     4.3.1 Nasopharyngeal Swabs
  60.     4.3.2 Oropharyngeal Swabs
  61.     4.3.3 Saliva
  62.     4.3.4 Serum
  63.   4.4 Construction, BY Distribution Channel (USD Million)
  64.     4.4.1 Direct Sales
  65.     4.4.2 Retail Pharmacies
  66.     4.4.3 Online Sales
  67. 5 SECTION V: COMPETITIVE ANALYSIS
  68.   5.1 Competitive Landscape
  69.     5.1.1 Overview
  70.     5.1.2 Competitive Analysis
  71.     5.1.3 Market share Analysis
  72.     5.1.4 Major Growth Strategy in the Construction
  73.     5.1.5 Competitive Benchmarking
  74.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  75.     5.1.7 Key developments and growth strategies
  76.       5.1.7.1 New Product Launch/Service Deployment
  77.       5.1.7.2 Merger & Acquisitions
  78.       5.1.7.3 Joint Ventures
  79.     5.1.8 Major Players Financial Matrix
  80.       5.1.8.1 Sales and Operating Income
  81.       5.1.8.2 Major Players R&D Expenditure. 2023
  82.   5.2 Company Profiles
  83.     5.2.1 Abbott Laboratories (US)
  84.       5.2.1.1 Financial Overview
  85.       5.2.1.2 Products Offered
  86.       5.2.1.3 Key Developments
  87.       5.2.1.4 SWOT Analysis
  88.       5.2.1.5 Key Strategies
  89.     5.2.2 Roche Diagnostics (CH)
  90.       5.2.2.1 Financial Overview
  91.       5.2.2.2 Products Offered
  92.       5.2.2.3 Key Developments
  93.       5.2.2.4 SWOT Analysis
  94.       5.2.2.5 Key Strategies
  95.     5.2.3 Thermo Fisher Scientific (US)
  96.       5.2.3.1 Financial Overview
  97.       5.2.3.2 Products Offered
  98.       5.2.3.3 Key Developments
  99.       5.2.3.4 SWOT Analysis
  100.       5.2.3.5 Key Strategies
  101.     5.2.4 Siemens Healthineers (DE)
  102.       5.2.4.1 Financial Overview
  103.       5.2.4.2 Products Offered
  104.       5.2.4.3 Key Developments
  105.       5.2.4.4 SWOT Analysis
  106.       5.2.4.5 Key Strategies
  107.     5.2.5 BD (US)
  108.       5.2.5.1 Financial Overview
  109.       5.2.5.2 Products Offered
  110.       5.2.5.3 Key Developments
  111.       5.2.5.4 SWOT Analysis
  112.       5.2.5.5 Key Strategies
  113.     5.2.6 Cepheid (US)
  114.       5.2.6.1 Financial Overview
  115.       5.2.6.2 Products Offered
  116.       5.2.6.3 Key Developments
  117.       5.2.6.4 SWOT Analysis
  118.       5.2.6.5 Key Strategies
  119.     5.2.7 Hologic (US)
  120.       5.2.7.1 Financial Overview
  121.       5.2.7.2 Products Offered
  122.       5.2.7.3 Key Developments
  123.       5.2.7.4 SWOT Analysis
  124.       5.2.7.5 Key Strategies
  125.     5.2.8 PerkinElmer (US)
  126.       5.2.8.1 Financial Overview
  127.       5.2.8.2 Products Offered
  128.       5.2.8.3 Key Developments
  129.       5.2.8.4 SWOT Analysis
  130.       5.2.8.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 CHINA MARKET ANALYSIS BY TEST TYPE
  137.   6.3 CHINA MARKET ANALYSIS BY END USER
  138.   6.4 CHINA MARKET ANALYSIS BY SAMPLE TYPE
  139.   6.5 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  140.   6.6 KEY BUYING CRITERIA OF CONSTRUCTION
  141.   6.7 RESEARCH PROCESS OF MRFR
  142.   6.8 DRO ANALYSIS OF CONSTRUCTION
  143.   6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  144.   6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  145.   6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
  146.   6.12 CONSTRUCTION, BY TEST TYPE, 2024 (% SHARE)
  147.   6.13 CONSTRUCTION, BY TEST TYPE, 2024 TO 2035 (USD Million)
  148.   6.14 CONSTRUCTION, BY END USER, 2024 (% SHARE)
  149.   6.15 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
  150.   6.16 CONSTRUCTION, BY SAMPLE TYPE, 2024 (% SHARE)
  151.   6.17 CONSTRUCTION, BY SAMPLE TYPE, 2024 TO 2035 (USD Million)
  152.   6.18 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  153.   6.19 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  154.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  155. 7 LIST OF TABLES
  156.   7.1 LIST OF ASSUMPTIONS
  157.     7.1.1
  158.   7.2 China MARKET SIZE ESTIMATES; FORECAST
  159.     7.2.1 BY TEST TYPE, 2025-2035 (USD Million)
  160.     7.2.2 BY END USER, 2025-2035 (USD Million)
  161.     7.2.3 BY SAMPLE TYPE, 2025-2035 (USD Million)
  162.     7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  163.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  164.     7.3.1
  165.   7.4 ACQUISITION/PARTNERSHIP
  166.     7.4.1

China Construction Market Segmentation

Construction By Test Type (USD Million, 2025-2035)

  • PCR Tests
  • Antigen Tests
  • Antibody Tests
  • CRISPR Tests

Construction By End User (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Laboratories
  • Home Care

Construction By Sample Type (USD Million, 2025-2035)

  • Nasopharyngeal Swabs
  • Oropharyngeal Swabs
  • Saliva
  • Serum

Construction By Distribution Channel (USD Million, 2025-2035)

  • Direct Sales
  • Retail Pharmacies
  • Online Sales

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions